cometadata/datacite-titles-descriptions-related-identifiers huggingface dataset:
DOI: 10.13145/bacdive20475.20201210.5
title: Corallococcus coralloides

description: The range of data encompasses taxonomy, morphology, physiology, sampling and concomitant environmental conditions as well as molecular biology.
DOI: 10.13145/bacdive20476.20201210.5
title: Corallococcus coralloides

description: The range of data encompasses taxonomy, morphology, physiology, sampling and concomitant environmental conditions as well as molecular biology.
DOI: 10.13145/bacdive20477.20201210.5
title: Corallococcus coralloides

description: The range of data encompasses taxonomy, morphology, physiology, sampling and concomitant environmental conditions as well as molecular biology.
DOI: 10.34740/kaggle/dsv/3053575
title: YouTube Trending Video Dataset (updated daily)
DOI: 10.6084/m9.figshare.17128658
title: Supplementary Material for: Effects of washed microbiota transplantation on serum uric acid levels, symptoms and intestinal barrier function in patients with acute and recurrent gout: a pilot study

description: Introduction: Gut dysbiosis has been reported to be closely associated with gout. Washed microbiota transplantation (WMT) is considered as an effective way to restore a healthy gut microbiota with less adverse events than the conventional fecal microbiota transplantation. In this study, we aimed to evaluate the effects of WMT on serum uric acid levels, symptoms and the intestinal barrier function in patients with acute and recurrent gout. Methods: We performed a pilot study of WMT for acute and recurrent gout. The primary outcome was the changes in serum uric acid level and gout symptoms. The secondary outcomes included the changes in levels of diamine oxidase (DAO), D-lactic acid and endotoxin. Results: Eleven patients received WMT treatment. The averaged serum uric acid levels in patients with gout reduced after WMT (P = 0.031), accompanied with a decrease in the frequency and duration time of acute gout flares (P &lt; 0.01). The levels of DAO, D-lactic acid and endotoxin were higher in patients than in healthy donors (P &lt; 0.05). After WMT treatment, the levels of DAO and endotoxin decreased (P &lt; 0.05). Conclusions: WMT is effective for reducing serum uric acid levels and improving gout symptoms in patients with gout, and contributes to improve their impaired intestinal barrier function.
DOI: 10.5517/ccdc.csd.cc1nzjv0
title: CCDC 1548693: Experimental Crystal Structure Determination

description: Related Article: Evan P. Vanable, Seth E. Ensign, An T. Ho, Gregory D. Kortman, Kami L. Hull|2021|CSD Communication|||
DOI: 10.5517/ccdc.csd.cc21nvwg
title: CCDC 1896886: Experimental Crystal Structure Determination

description: Related Article: Arnold L. Rheingold and Glenn Yap|2019|CSD Communication|||
DOI: 10.5517/ccdc.csd.cc21y9lx
title: CCDC 1904999: Experimental Crystal Structure Determination

description: Related Article: Sennappan M|2019|CSD Communication|||
DOI: 10.5517/ccdc.csd.cc221f3p
title: CCDC 1907991: Experimental Crystal Structure Determination

description: Related Article: Mercedes Sanaú, Francisco Estevan, Angeles Úbeda|2019|CSD Communication|||
DOI: 10.5517/ccdc.csd.cc28ywhm
title: CCDC 2114091: Experimental Crystal Structure Determination

description: Related Article: MAVIS DAMBI|2021|CSD Communication|||
DOI: 10.5517/ccdc.csd.cc28z9td
title: CCDC 2114504: Experimental Crystal Structure Determination

description: Related Article: J.C. Hilario-Martinez, S. Bernes, J. Sandoval-Ramirez, M.A. Fernandez-Herrera|2021|CSD Communication|||
DOI: 10.5517/ccdc.csd.cc28zdym
title: CCDC 2114601: Experimental Crystal Structure Determination

description: Related Article: Mucahit Mozdemir|2021|CSD Communication|||
DOI: 10.5517/ccdc.csd.cc28zdzn
title: CCDC 2114602: Experimental Crystal Structure Determination

description: Related Article: Mucahit Ozdemir|2021|CSD Communication|||
DOI: 10.5517/ccdc.csd.cc272knk
title: CCDC 2058048: Experimental Crystal Structure Determination

description: Related Article: Shan Shan|2021|CSD Communication|||
description: Related Article: Shanshan Shi, Zhipeng Zheng, Yumeng Zhang, Yufei Yang, Denghui Ma, Yuzhen Gao, Yan Liu, Guo Tang, Yufen Zhao|2021|Org.Lett.|23|9348|doi:10.1021/acs.orglett.1c03360
DOI: 10.5517/ccdc.csd.cc28zjf7
title: CCDC 2114709: Experimental Crystal Structure Determination

description: Related Article: Noha Ahmed, Jeanette A. Krause, Anna D. Gundmundsdottir|2021|CSD Communication|||
DOI: 10.5517/ccdc.csd.cc28zjg8
title: CCDC 2114710: Experimental Crystal Structure Determination

description: Related Article: Noha Ahmed, Jeanette A. Krause, Anna D. Gundmundsdottir|2021|CSD Communication|||
DOI: 10.5517/ccdc.csd.cc28zjh9
title: CCDC 2114711: Experimental Crystal Structure Determination

description: Related Article: Noha Ahmed, Jeanette A. Krause, Anna D. Gundmundsdottir|2021|CSD Communication|||
DOI: 10.5517/ccdc.csd.cc28zjjb
title: CCDC 2114712: Experimental Crystal Structure Determination

description: Related Article: Noha Ahmed, Jeanette A. Krause, Anna D. Gundmundsdottir|2021|CSD Communication|||
DOI: 10.6084/m9.figshare.17129720
title: Supplementary Material for: Efficacy of the BNT162b2 mRNA COVID-19 Vaccine in Patients with Chronic Lymphocytic Leukemia: A Serologic and Cellular Study

description: Background: Antibody response following SARS-CoV2 vaccination is somewhat defective in chronic lymphocytic leukemia (CLL). Moreover, the correlation between serologic response and status of cellular immunity has been poorly studied. Objective: This study was undertaken to assess humoral immune and cellular responses to the BNT162b2 messenger RNA (mRNA) COVID-19 vaccination in CLL. Methods: The presence of the spike antibodies was assessed at a median time of 14 days from the second vaccine dose of SARS-CoV2 in 70 CLL followed-up at a single institution. Results: The antibody response rate (RR) in CLL patients was 58.5%, compared to 100% of 57 healthy controls of the same sex and age (P&lt; 0.0001). Patients treatment-naïve and those in sustained clinical remission after therapy had the highest RR (87.0% and 87.7%, respectively). In contrast, patients on therapy with a pathway inhibitor as monotherapy and those treated with an association of anti-CD20 antibody were unlikely to respond to the SARS-CoV-2 vaccine (52% and 10%, respectively). In multivariate analysis, early Rai stage (OR, 0.19 [0.05-0.79]; P=0.02) and no previous therapy (OR, 0.06[0.02-0.27]; P&lt;0.0001) were found to be independent predictors of vaccination response. An increase in absolute NK cells (i.e., CD16/CD56 positive cells) in patients with a serological response was found following the second dose of vaccine (P=0.02). Conclusions: These results confirm that serological response to the BNT162b2 vaccine in patients with CLL is impaired. A third boosting vaccine dosage should be considered for these patients.
DOI: 10.6084/m9.figshare.17129720.v1
title: Supplementary Material for: Efficacy of the BNT162b2 mRNA COVID-19 Vaccine in Patients with Chronic Lymphocytic Leukemia: A Serologic and Cellular Study

description: Background: Antibody response following SARS-CoV2 vaccination is somewhat defective in chronic lymphocytic leukemia (CLL). Moreover, the correlation between serologic response and status of cellular immunity has been poorly studied. Objective: This study was undertaken to assess humoral immune and cellular responses to the BNT162b2 messenger RNA (mRNA) COVID-19 vaccination in CLL. Methods: The presence of the spike antibodies was assessed at a median time of 14 days from the second vaccine dose of SARS-CoV2 in 70 CLL followed-up at a single institution. Results: The antibody response rate (RR) in CLL patients was 58.5%, compared to 100% of 57 healthy controls of the same sex and age (P&lt; 0.0001). Patients treatment-naïve and those in sustained clinical remission after therapy had the highest RR (87.0% and 87.7%, respectively). In contrast, patients on therapy with a pathway inhibitor as monotherapy and those treated with an association of anti-CD20 antibody were unlikely to respond to the SARS-CoV-2 vaccine (52% and 10%, respectively). In multivariate analysis, early Rai stage (OR, 0.19 [0.05-0.79]; P=0.02) and no previous therapy (OR, 0.06[0.02-0.27]; P&lt;0.0001) were found to be independent predictors of vaccination response. An increase in absolute NK cells (i.e., CD16/CD56 positive cells) in patients with a serological response was found following the second dose of vaccine (P=0.02). Conclusions: These results confirm that serological response to the BNT162b2 vaccine in patients with CLL is impaired. A third boosting vaccine dosage should be considered for these patients.
DOI: 10.5281/zenodo.5863745
title: Comparative genomics of eight aphid subfamilies reveals variable relationships between host horizontally-transferred genes and symbiont peptidoglycan metabolism.

description: Genome assemblies, annotations, and orthologs of aphids (<em>Geopemphigus sp.</em>, <em>Stegophylla sp.</em>, <em>Chaitophorus viminalis</em>, and<em> Pemphigus obesinymphae</em>) and their symbionts. step1_final_assemblies_and_annotations.tar.gz: Aphid genomes and annotations step2_protein_evidence_used_for_genome_annotation.tar.gz: Protein evidence used for aphid genome annotation step3_amino_acid_inputs_for_aphid_orthologs: amino acid inputs for aphid ortholog assignmentt step5_buchnera_genomes_and_annotations.tar.gz: Buchnera genomes and annotations
DOI: 10.5281/zenodo.5484414
title: Comparative genomics of eight aphid subfamilies reveals variable relationships between host horizontally-transferred genes and symbiont peptidoglycan metabolism.

description: Genome assemblies, annotations, and orthologs of aphids (<em>Geopemphigus sp.</em>, <em>Stegophylla sp.</em>, <em>Chaitophorus viminalis</em>, and<em> Pemphigus obesinymphae</em>) and their symbionts. step1_final_assemblies_and_annotations.tar.gz: Aphid genomes and annotations step2_protein_evidence_used_for_genome_annotation.tar.gz: Protein evidence used for aphid genome annotation step3_amino_acid_inputs_for_aphid_orthologs: amino acid inputs for aphid ortholog assignmentt step5_buchnera_genomes_and_annotations.tar.gz: Buchnera genomes and annotations
DOI: 10.34740/kaggle/dsv/3053614
title: 2021 World Population (updated daily)
DOI: 10.5281/zenodo.5863567
title: Heterobranchus longifilis decontaminated FSCR

description: .
DOI: 10.5281/zenodo.5863566
title: Heterobranchus longifilis decontaminated FSCR

description: .
DOI: 10.5281/zenodo.5863593
title: Himantozoum antarcticum decontaminated FSCR

description: .
DOI: 10.5281/zenodo.5863592
title: Himantozoum antarcticum decontaminated FSCR

description: .
DOI: 10.5281/zenodo.5856250
title: K9Stiffness

description: No
DOI: 10.5281/zenodo.5856249
title: K9Stiffness

description: No
DOI: 10.6084/m9.figshare.17185685
title: Supplementary Material for: High glycemic variability is associated with worse Continuous Glucose Monitoring metrics in children and adolescents with type 1 diabetes

description: Objective: The primary aim of this study was to quantify the prevalence of children and adolescents with T1D who achieve the recommended target for CV identifying the determining factors to reach this target. The secondary aim was to examine the relationship between CV, the other metrics derived from CGM data and clinical parameters. Method: CGM data were collected from 805 children/adolescents with T1D. Several CGM metrics and patients' characteristics were evaluated. Participants were stratified by CV≤36% and CV&gt;36%. Binary logistic regression analysis was run to identify the determining factors of high CV. Results CV was positively correlated with %TBR&lt;70mg/dL, %TBR&lt;54 mg/dL, %TAR&gt;250 mg/dL, LBGI, HBGI and negatively with %TIR. CV≤36% was found in 31.4% of the subjects. The CV&gt;36% group spent less time in %TIR, more time in hypoglycemia and hyperglycemia with lower proportion of subjects using rtCGM and CSII. Percentage of TBR&lt;70mg/dL and TAR&gt;250mg/dL were significant predictors of CV&gt;36%, whereas age, gender, BMI, duration of diabetes, type of CGM device, type of insulin therapy administration and %TIR were not significant predictors (p&lt;0.001,R2Nagelkerke=0.48). Conclusions: CV identifies children and adolescents with worse glycemic control at higher risk of both hypoglycemia and hyperglycemia.
DOI: 10.6084/m9.figshare.17185685.v1
title: Supplementary Material for: High glycemic variability is associated with worse Continuous Glucose Monitoring metrics in children and adolescents with type 1 diabetes

description: Objective: The primary aim of this study was to quantify the prevalence of children and adolescents with T1D who achieve the recommended target for CV identifying the determining factors to reach this target. The secondary aim was to examine the relationship between CV, the other metrics derived from CGM data and clinical parameters. Method: CGM data were collected from 805 children/adolescents with T1D. Several CGM metrics and patients' characteristics were evaluated. Participants were stratified by CV≤36% and CV&gt;36%. Binary logistic regression analysis was run to identify the determining factors of high CV. Results CV was positively correlated with %TBR&lt;70mg/dL, %TBR&lt;54 mg/dL, %TAR&gt;250 mg/dL, LBGI, HBGI and negatively with %TIR. CV≤36% was found in 31.4% of the subjects. The CV&gt;36% group spent less time in %TIR, more time in hypoglycemia and hyperglycemia with lower proportion of subjects using rtCGM and CSII. Percentage of TBR&lt;70mg/dL and TAR&gt;250mg/dL were significant predictors of CV&gt;36%, whereas age, gender, BMI, duration of diabetes, type of CGM device, type of insulin therapy administration and %TIR were not significant predictors (p&lt;0.001,R2Nagelkerke=0.48). Conclusions: CV identifies children and adolescents with worse glycemic control at higher risk of both hypoglycemia and hyperglycemia.
DOI: 10.6084/m9.figshare.3761562.v2107
title: Online Labour Index: Measuring the Online Gig Economy for Policy and Research

description: Data repository for the data underlying the Online Labour Index. See http://ilabour.oii.ox.ac.uk online-labour-index/ for details.
DOI: 10.6084/m9.figshare.17158925
title: Supplementary Material for: Antibody response to SARS-CoV-2 vaccination in patients with inflammatory bowel disease – results of a single-center cohort study in a tertiary hospital in Germany

description: COVID-19 was first described in 2019, with significant impact on everyday life since then. In 2020, the first vaccine against COVID-19 was approved. Little is known about immune response to vaccination in patients with inflammatory bowel disease (IBD). Aim of our study was to investigate antibody response to SARS-CoV-2 vaccination in IBD patients receiving immunomodulators/biologics compared to healthy controls. This was a single-center retrospective study. 72 patients with IBD were included. Data from 72 healthy employees were used as control group matched by propensity score. Blood samples were analyzed for antibody response. 65 (90.3%) patients of the IBD group received immunomodulatory therapy. Mean antibody level for IBD patients was 1257.1 U/ml (SD 1109.626) in males and 1500.1 U/ml (SD 1142.760) in females (reduced antibody response IBD group 1383.76 U/ml SD 1125.617; control group 1885.65 U/ml SD 727.572, p &lt; 0.05)). There was no vaccination failure in IBD group. After first vaccination, side effects were reported more often in IBD patients (total symptoms IBD group 58.3 %, control group 34.5 %, p &lt; 0.007) with the opposite after the second vaccination (total symptoms IBD group 55.4 %, control group 76 %, p = 0.077)). There was a trend to reduced immune response in elderly. Disease duration and immunomodulatory therapy had no impact on immune response. Longer time to last medication given and time passed to vaccination in IBD group seem to have a positive impact on antibody levels. High antibody response to vaccination in all patients with IBD was seen. Vaccination was well tolerated. Concomitant immunomodulatory therapy had no impact on seroconversion. Antibody levels in the IBD group were lower compared to control group.
DOI: 10.6084/m9.figshare.17158925.v1
title: Supplementary Material for: Antibody response to SARS-CoV-2 vaccination in patients with inflammatory bowel disease – results of a single-center cohort study in a tertiary hospital in Germany

description: COVID-19 was first described in 2019, with significant impact on everyday life since then. In 2020, the first vaccine against COVID-19 was approved. Little is known about immune response to vaccination in patients with inflammatory bowel disease (IBD). Aim of our study was to investigate antibody response to SARS-CoV-2 vaccination in IBD patients receiving immunomodulators/biologics compared to healthy controls. This was a single-center retrospective study. 72 patients with IBD were included. Data from 72 healthy employees were used as control group matched by propensity score. Blood samples were analyzed for antibody response. 65 (90.3%) patients of the IBD group received immunomodulatory therapy. Mean antibody level for IBD patients was 1257.1 U/ml (SD 1109.626) in males and 1500.1 U/ml (SD 1142.760) in females (reduced antibody response IBD group 1383.76 U/ml SD 1125.617; control group 1885.65 U/ml SD 727.572, p &lt; 0.05)). There was no vaccination failure in IBD group. After first vaccination, side effects were reported more often in IBD patients (total symptoms IBD group 58.3 %, control group 34.5 %, p &lt; 0.007) with the opposite after the second vaccination (total symptoms IBD group 55.4 %, control group 76 %, p = 0.077)). There was a trend to reduced immune response in elderly. Disease duration and immunomodulatory therapy had no impact on immune response. Longer time to last medication given and time passed to vaccination in IBD group seem to have a positive impact on antibody levels. High antibody response to vaccination in all patients with IBD was seen. Vaccination was well tolerated. Concomitant immunomodulatory therapy had no impact on seroconversion. Antibody levels in the IBD group were lower compared to control group.
DOI: 10.6084/m9.figshare.3761562.v2108
title: Online Labour Index: Measuring the Online Gig Economy for Policy and Research

description: Data repository for the data underlying the Online Labour Index. See http://ilabour.oii.ox.ac.uk online-labour-index/ for details.
DOI: 10.6084/m9.figshare.18517823
title: Supplementary Material for: Systematic Investigation of SARS-CoV-2 Receptor Protein Distribution along Viral Entry Routes in Humans

description: <b><i>Background:</i></b> The novel beta-coronavirus, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), enters the human body via mucosal surfaces of the upper and/or lower respiratory tract. Viral entry into epithelial cells is mediated via angiotensin-converting enzyme 2 (ACE2) and auxiliary molecules, but the precise anatomic site of infection still remains unclear. <b><i>Methods:</i></b> Here, we systematically investigated the main SARS-CoV-2 receptor proteins ACE2 and transmembrane serine protease 2 (TMPRSS2), as well as 2 molecules potentially involved in viral entry, furin and CD147, in formalin-fixed, paraffin-embedded human tissues. Tissue microarrays incorporating a total of 879 tissue cores from conjunctival (<i>n</i> = 84), sinonasal (<i>n</i> = 95), and lung (bronchiolar/alveolar; <i>n</i> = 96) specimens were investigated for protein expression by immunohistochemistry. <b><i>Results:</i></b> ACE2 and TMPRSS2 were expressed in ciliated epithelial cells of the conjunctivae and sinonasal tissues, with highest expression levels observed in the apical cilia. In contrast, in the lung, the expression of those molecules in bronchiolar and alveolar epithelial cells was much rarer and only very focal when present. Furin and CD147 were more uniformly expressed in all tissues analyzed, including the lung. Interestingly, alveolar macrophages consistently expressed high levels of all 4 molecules investigated. <b><i>Conclusions:</i></b> Our study confirms and extends previous findings and contributes to a better understanding of potential SARS-CoV-2 infection sites along the human respiratory tract.
DOI: 10.6084/m9.figshare.18517823.v1
title: Supplementary Material for: Systematic Investigation of SARS-CoV-2 Receptor Protein Distribution along Viral Entry Routes in Humans

description: <b><i>Background:</i></b> The novel beta-coronavirus, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), enters the human body via mucosal surfaces of the upper and/or lower respiratory tract. Viral entry into epithelial cells is mediated via angiotensin-converting enzyme 2 (ACE2) and auxiliary molecules, but the precise anatomic site of infection still remains unclear. <b><i>Methods:</i></b> Here, we systematically investigated the main SARS-CoV-2 receptor proteins ACE2 and transmembrane serine protease 2 (TMPRSS2), as well as 2 molecules potentially involved in viral entry, furin and CD147, in formalin-fixed, paraffin-embedded human tissues. Tissue microarrays incorporating a total of 879 tissue cores from conjunctival (<i>n</i> = 84), sinonasal (<i>n</i> = 95), and lung (bronchiolar/alveolar; <i>n</i> = 96) specimens were investigated for protein expression by immunohistochemistry. <b><i>Results:</i></b> ACE2 and TMPRSS2 were expressed in ciliated epithelial cells of the conjunctivae and sinonasal tissues, with highest expression levels observed in the apical cilia. In contrast, in the lung, the expression of those molecules in bronchiolar and alveolar epithelial cells was much rarer and only very focal when present. Furin and CD147 were more uniformly expressed in all tissues analyzed, including the lung. Interestingly, alveolar macrophages consistently expressed high levels of all 4 molecules investigated. <b><i>Conclusions:</i></b> Our study confirms and extends previous findings and contributes to a better understanding of potential SARS-CoV-2 infection sites along the human respiratory tract.
DOI: 10.5281/zenodo.5863653
title: Hiodon alosoides decontaminated FSCR

description: .
DOI: 10.5281/zenodo.5863652
title: Hiodon alosoides decontaminated FSCR

description: .
DOI: 10.5281/zenodo.5864325
title: msd-errors - Data for the LLZO figure

description: Data for the figure showing the diffusion and Arrhenius plots for a short simulation of LLZO. <br><br>Created using showyourwork from this GitHub repo.<br>
DOI: 10.6084/m9.figshare.15200286.v5
title: Scoping review of systematic reviews and meta-analyses of interventions designed to improve vaccination uptake.

description: Vaccine uptake varies substantially and resources to promote uptake varies widely by country and income level, and immunization rates are often suboptimal. We, therefore conducted a scoping review of interventions designed to increase vaccination uptake and have steored the tables and appendices in Figshare for access.pendix<br><b>Appendices</b>Appendix 1. Protocol_Vaccine Uptake_V1_2021.docxAppendix 2. Excluded Discordant Review references Appendix 3. Included References for GRADE Assessment (n=107)Appendix 4. Glossary of Intervention definitions Appendix 5. Multiple Intervention components across 37 SRs Appendix 6. Excluded reviews from GRADE (on full-text assessment)Appendix 7. Vaccine Uptake Tracker <b>Figures </b>Figure 1. Vaccine Uptake Flow chart & InclusionFigure 2. Vaccine Uptake Flow chart by year <b>Tables</b>Table 1. Outcomes of Interest and Prioritization Table 2. Summary of Intervention coverage and populationsTable 3. AMSTAR Score Vaccine Uptake Reviews Table 4. GRADE Tables Vaccine Uptake Reviews Table 5. Study Characteristics Vaccine Uptake SRs
DOI: 10.5281/zenodo.5834594
title: Data for "Exemplifying parametric timed specifications over signals with bounded behavior"

description: Data for "Exemplifying parametric timed specifications over signals with bounded behavior" See README.md in the zipped file for explanations and instructions for reproductibility.
DOI: 10.5281/zenodo.5863797
title: Holothuria glaberrima decontaminated FSCR

description: .
DOI: 10.5281/zenodo.5863796
title: Holothuria glaberrima decontaminated FSCR

description: .